{"id":13775,"date":"2025-08-21T17:04:44","date_gmt":"2025-08-21T11:34:44","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=13775"},"modified":"2025-08-21T17:04:44","modified_gmt":"2025-08-21T11:34:44","slug":"anlon-healthcare-ltd-ipo-opens","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/anlon-healthcare-ltd-ipo-opens\/","title":{"rendered":"Anlon Healthcare Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/b>The <\/span>healthcare sector<\/span><\/a> continues to be a key focus for investors, with a steady stream of new offerings. Riding this momentum, Anlon Healthcare Limited, a Rajkot-based manufacturer of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), has opened its IPO on August 26, 2025.<\/span><\/p>\n

Here is a detailed insight into the <\/span>Anlon Healthcare IPO details<\/span><\/a> and the industry outlook.<\/span><\/p>\n

<\/span>About Anlon Healthcare Ltd.<\/b><\/span><\/h2>\n

Established in 2013, Anlon Healthcare Ltd. is a research-intensive company specialising in the manufacturing of high-purity advanced pharmaceutical intermediates and APIs. The company’s product portfolio includes pharmaceutical intermediates, APIs, nutraceutical APIs, and ingredients for personal care and veterinary use. The company is one of the few manufacturers of loxoprofen sodium dihydrate in India, an API used for treating pain and inflammation.<\/span><\/p>\n

Anlon Healthcare’s products adhere to Indian and international pharmacopoeia standards (IP, BP, EP, JP, USP). It has also received Drug Master File (DMF) approval from international regulatory bodies like ANVISA, NMPA, and PMDA. The company is engaged in custom manufacturing services for complex chemical compounds, tailoring production processes to meet specific client needs.<\/span><\/p>\n

<\/span>Anlon Healthcare Ltd. IPO Details<\/b><\/span><\/h2>\n

The Anlon Healthcare IPO is a book-building issue of \u20b9121.03 crore. The entire issue is a fresh issuance of 1.33 crore shares. The company plans to use the net proceeds to fund capital expenditure for proposed expansions, repay certain secured borrowings, and for working capital and general corporate purposes.<\/span><\/p>\n

<\/span>Important IPO Timeline<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Event<\/b><\/td>\nDate<\/b><\/td>\n<\/tr>\n
IPO Open Date<\/b><\/td>\nTuesday, August 26, 2025<\/span><\/td>\n<\/tr>\n
IPO Close Date<\/b><\/td>\nFriday, August 29, 2025<\/span><\/td>\n<\/tr>\n
Cut-off Time for UPI Mandate Confirmation<\/b><\/td>\n5:00 PM on August 29, 2025<\/span><\/td>\n<\/tr>\n
Tentative Allotment Date<\/b><\/td>\nMonday, September 1, 2025<\/span><\/td>\n<\/tr>\n
Initiation of Refunds<\/b><\/td>\nTuesday, September 2, 2025<\/span><\/td>\n<\/tr>\n
Credit of Shares to Demat<\/b><\/td>\nTuesday, September 2, 2025<\/span><\/td>\n<\/tr>\n
Tentative Listing Date<\/b><\/td>\nWednesday, September 3, 2025<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Key IPO Details<\/b><\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/b><\/td>\nDetails<\/b><\/td>\n<\/tr>\n
IPO Date<\/b><\/td>\nAugust 26, 2025 to August 29, 2025<\/span><\/td>\n<\/tr>\n
Listing Date<\/b><\/td>\n–<\/span><\/td>\n<\/tr>\n
Face Value<\/b><\/td>\n\u20b910 per share<\/span><\/td>\n<\/tr>\n
Issue Price Band<\/b><\/td>\n\u20b986 to \u20b991 per share<\/span><\/td>\n<\/tr>\n
Lot Size<\/b><\/td>\n164 Shares<\/span><\/td>\n<\/tr>\n
Sale Type<\/b><\/td>\nFresh Capital<\/span><\/td>\n<\/tr>\n
Total Issue Size<\/b><\/td>\n\n

1,33,00,000 shares<\/span><\/p>\n

\u00a0(\u20b9121.03 Cr)<\/span><\/td>\n<\/tr>\n

Issue Type<\/b><\/td>\nBookbuilding IPO<\/span><\/td>\n<\/tr>\n
Listing At<\/b><\/td>\nBSE, NSE<\/span><\/td>\n<\/tr>\n
Share Holding Pre-Issue<\/b><\/td>\n3,98,51,500 shares<\/span><\/td>\n<\/tr>\n
Share Holding Post-Issue<\/b><\/td>\n5,31,51,500 shares<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/a><\/b><\/p>\n

<\/span>Lot Size of Anlon Healthcare Ltd. IPO<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n
Application<\/b><\/td>\nLots<\/b><\/td>\nShares<\/b><\/td>\nAmount<\/b><\/td>\n<\/tr>\n
Retail (Min)<\/b><\/td>\n1<\/span><\/td>\n164<\/span><\/td>\n\u20b914,924<\/span><\/td>\n<\/tr>\n
Retail (Max)<\/b><\/td>\n13<\/span><\/td>\n2,132<\/span><\/td>\n\u20b91,94,012<\/span><\/td>\n<\/tr>\n
S-HNI (Min)<\/b><\/td>\n14<\/span><\/td>\n2,296<\/span><\/td>\n\u20b92,08,936<\/span><\/td>\n<\/tr>\n
S-HNI (Max)<\/b><\/td>\n67<\/span><\/td>\n10,988<\/span><\/td>\n\u20b99,99,908<\/span><\/td>\n<\/tr>\n
B-HNI (Min)<\/b><\/td>\n68<\/span><\/td>\n11,152<\/span><\/td>\n\u20b910,14,832<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anlon Healthcare Ltd. Financials<\/b><\/span><\/h2>\n

As of January 31, 2025, Anlon Healthcare Ltd. has shown strong financial performance with assets amounting to \u20b9160.96 crore and a significant increase in profit after tax to \u20b911.96 crore. The company has demonstrated substantial growth in net worth, which reached \u20b971.86 crore compared to \u20b921.03 crore in the previous year. Despite fluctuations in total income across the years, the company’s reserves and surplus have improved, indicating better financial stability. Anlon Healthcare\u2019s total borrowing stands at \u20b962.39 crore, reflecting a manageable debt position.<\/span><\/p>\n

<\/span>Company Financial Snapshot\u00a0<\/b><\/span><\/h3>\n\n\n\n\n\n\n\n\n\n
Particulars (\u20b9 Crore)<\/b><\/td>\n31 Jan 2025<\/b><\/td>\n31 Mar 2024<\/b><\/td>\n31 Mar 2023<\/b><\/td>\n31 Mar 2022<\/b><\/td>\n<\/tr>\n
Assets<\/b><\/td>\n160.96<\/span><\/td>\n128<\/span><\/td>\n111.55<\/span><\/td>\n84.97<\/span><\/td>\n<\/tr>\n
Total Income<\/b><\/td>\n77.37<\/span><\/td>\n67<\/span><\/td>\n113.12<\/span><\/td>\n57.54<\/span><\/td>\n<\/tr>\n
Profit After Tax<\/b><\/td>\n11.96<\/span><\/td>\n10<\/span><\/td>\n5.82<\/span><\/td>\n-0.11<\/span><\/td>\n<\/tr>\n
Net Worth<\/b><\/td>\n71.86<\/span><\/td>\n21<\/span><\/td>\n7.37<\/span><\/td>\n1.55<\/span><\/td>\n<\/tr>\n
Reserves and Surplus<\/b><\/td>\n32.01<\/span><\/td>\n5.03<\/span><\/td>\n-4.63<\/span><\/td>\n-10.24<\/span><\/td>\n<\/tr>\n
Total Borrowing<\/b><\/td>\n62.39<\/span><\/td>\n74.56<\/span><\/td>\n66.39<\/span><\/td>\n60.32<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anlon Healthcare Ltd.: Industry Outlook<\/b><\/span><\/h2>\n

The <\/span>pharmaceutical sector<\/span><\/a> in India is experiencing robust growth, driven by increasing healthcare spending, a growing population, and rising chronic diseases. As a manufacturer of APIs and intermediates, Anlon Healthcare is well-positioned to benefit from this expansion. The company\u2019s focus on high-purity products and its DMF approvals from international bodies give it a competitive edge in the domestic and global markets.<\/span><\/p>\n

However, investors should be aware of potential risks, including intense competition from domestic and international players and regulatory challenges.<\/span><\/p>\n

<\/span>Use of IPO Proceeds<\/b><\/span><\/h2>\n

The net proceeds from the fresh issue will be utilised for:<\/span><\/p>\n\n\n\n\n\n\n\n
S.No.<\/b><\/td>\nPurpose of the Issue<\/b><\/td>\nExpected Amount ((\u20b9 Cr)<\/b><\/td>\n<\/tr>\n
1<\/span><\/td>\nFunding capital expenditure requirements for the proposed expansion<\/span><\/td>\n3,072<\/span><\/td>\n<\/tr>\n
2<\/span><\/td>\nFull or part repayment and\/or prepayment of certain outstanding secured borrowings (term loan)<\/span><\/td>\n500<\/span><\/td>\n<\/tr>\n
3<\/span><\/td>\nFunding the working capital requirements of the company<\/span><\/td>\n4,315<\/span><\/td>\n<\/tr>\n
4<\/span><\/td>\nGeneral corporate purposes<\/span><\/td>\n–<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anlon Healthcare IPO Peer Comparison<\/b><\/span><\/h2>\n

The pharmaceutical and speciality chemicals sector is highly competitive. Anlon Healthcare’s key listed peers include <\/span>Kronox Lab Sciences Limited<\/span><\/a>, <\/span>Acutaas Chemicals Limited<\/span><\/a>, and <\/span>Supriya Lifescience Limited<\/span><\/a>. When evaluating the Anlon Healthcare IPO, investors should consider its market positioning and growth potential relative to these peers, looking at factors like financial health, product diversification, and scalability.<\/span><\/p>\n

<\/span>Conclusion<\/b><\/span><\/h2>\n

The Anlon Healthcare IPO offers investors a chance to invest in a growing company within the dynamic pharmaceutical and speciality chemicals sector. The company’s strong financial performance and strategic use of IPO funds for expansion and debt repayment suggest a positive long-term outlook.<\/span><\/p>\n

As a mainline IPO, it is an opportunity for investors with a moderate to high-risk appetite and a long-term investment horizon. A thorough review of the company’s financials and market position is recommended before making an investment decision.<\/span>[\/vc_column_text][vc_column_text css=””]<\/p>\n

<\/h2>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Rate this article<\/h6>\n